Swiss Startups Allegria, Mabylon, and Alivion Receive EUR 2.8M Eureka Funding
Three Swiss firms, Allegria Therapeutics, Mabylon, and Alivion, have secured a total of EUR 2.8 million in non-dilutive funding through Eureka's Eurostars and Innowwide programs to advance drug development and market feasibility studies in their respective fields. This funding supports innovative therapies for chronic urticaria, inflammatory bowel disease, and portable methanol detection in Brazil.
Theia Market Signal Identification - AI Assisted
Allegria Therapeutics has coordinated the MastCURe consortium, receiving EUR 1.3 million in Eurostars funding for chronic urticaria therapies. This project combines expertise from Cube Biotech and the Fraunhofer Institute, targeting aberrant mast cell activation.
Mabylon's ASCEND project has secured EUR 1.46 million, focusing on the MY012 monoclonal antibody for inflammatory bowel disease, in collaboration with the Karolinska Institutet and Ambiotis. Alivion received EUR 60,000 for a market feasibility study of its Spark M-20 portable methanol detector in Brazil, focusing on food safety. The outcomes of these projects may influence treatment options and market strategies in their respective areas.
Comments